Oxford Biomedica PLC
03 February 2006
For immediate release 3 FEBRUARY 2006
OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT
Oxford, UK: 3 February 2006 - Oxford BioMedica (LSE: OXB), the leading gene
therapy company, today announces that, with immediate effect, Dr Mike McDonald
has been promoted to the Board as an executive director. He will maintain his
title of Chief Medical Officer. His primary responsibilities include the
Company's clinical development activities and regulatory affairs.
Mike has over 20 years of experience in clinical drug development and regulatory
leadership. He joined Oxford BioMedica in September 2005 from Seattle Genetics,
a US based biotechnology company, where he was Chief Medical Officer. Mike
spent nine years with Eli Lilly serving as Worldwide Vice President, Clinical
Research and Medical Affairs, and was previously at SmithKline Beecham for seven
years where he was involved in worldwide clinical development, regulatory
management and was a member of the pharmaceutical development strategy
committee. From these positions Dr McDonald contributed to the successful
registration and commercialisation of many important pharmaceuticals. He
received his medical degree from Edinburgh University, he is a member of the
Royal College of Physicians in London, holds a Diploma in Pharmaceutical
Medicine and is a Fellow of the Faculty of Pharmaceutical Physicians.
Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said: 'Mike has already made a significant and valuable
contribution to the Company since joining last year and has been instrumental in
the preparations for our planned Phase III trial of TroVax in renal cell
carcinoma. We are delighted to welcome him to the Board.'
There is no other information to be disclosed under Paragraph 9.6.13 R of the
Listing Rules.
-Ends-
For further information, please contact:
Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000
City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan Tel: +44 (0)20 7466 5000
Communications
Scientific/Trade Press Enquiries:
Katja Stout/ Gemma Bradley Tel: +44 (0)20 7886 8150
Northbank Communications
Notes to editors:
1. Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.
Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in 2006, and four further
preclinical candidates. The Company is underpinned by over 80 patent families,
which represent one of the broadest patent estates in the field.
The Company has a staff of approximately 70 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet,
Sigma-Aldrich, Viragen, MolMed and Kiadis; and has licensed technology to a
number of companies including Merck & Co, Biogen Idec and Pfizer.
Further information is available at www.oxfordbiomedica.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.